Table 2.
Demographic and clinical characteristics of the patients with primary VSCC. Numbers of samples are provided for the consecutive phases of the study.
| Characteristic | Stage of the Study | ||||
|---|---|---|---|---|---|
| iTRAQ Analysis |
Verification by PRM | IHC Analysis | ELISA Serum Testing |
||
| Age–years | Median | 70.0 | 70.8 | 70.4 | 72.6 |
| Range | 45.3–93.9 | 45.3–94.2 | 37.1–93.9 | 41.8–87.9 | |
| FIGO stage | I | 19 | 46 | 54 | 35 |
| II | 2 | 5 | 3 | 4 | |
| III | 7 | 24 | 29 | 22 | |
| IV | 0 | 1 | 0 | 3 | |
| Histological grade | G1 | 12 | 23 | 34 | 17 |
| G2 | 9 | 28 | 37 | 28 | |
| G3 | 6 | 12 | 12 | 6 | |
| N/D | 1 | 13 | 6 | 13 | |
| hrHPV tumor status | positive | 13 | 38 | 36 | 31 |
| negative | 15 | 27 | 32 | 6 | |
| N/D | 0 | 11 | 18 | 27 | |
| Disease progression | d-fVSCC | 16 | 25 | 50 | 33 |
| progVSCC | 12 | 26 | 34 | 31 | |
| prosVSCC | 0 | 25 | 3 | 0 | |
Abbreviations: iTRAQ, Isobaric tags for relative and absolute quantitation; PRM, parallel reaction monitoring; N/D, not determined.